Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FULC 
Fulcrum Therapeutics Inc (FULC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: FULC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.57
1 Year Target Price $7.57
| 2 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.21% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 383.25M USD | Price to earnings Ratio - | 1Y Target Price 7.57 |
Price to earnings Ratio - | 1Y Target Price 7.57 | ||
Volume (30-day avg) 7 | Beta 2.42 | 52 Weeks Range 2.31 - 10.13 | Updated Date 06/30/2025 |
52 Weeks Range 2.31 - 10.13 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.64% | Operating Margin (TTM) -13% |
Management Effectiveness
Return on Assets (TTM) -2.74% | Return on Equity (TTM) -0.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 164755072 | Price to Sales(TTM) 4.79 |
Enterprise Value 164755072 | Price to Sales(TTM) 4.79 | ||
Enterprise Value to Revenue 2.06 | Enterprise Value to EBITDA -3.09 | Shares Outstanding 53979300 | Shares Floating 24721982 |
Shares Outstanding 53979300 | Shares Floating 24721982 | ||
Percent Insiders 1.82 | Percent Institutions 96.2 |
Analyst Ratings
Rating 3 | Target Price 7.57 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Fulcrum Therapeutics Inc
Company Overview
History and Background
Fulcrum Therapeutics, founded in 2016, is a clinical-stage biopharmaceutical company focused on developing therapies for genetically defined diseases. They leverage their product engine to identify and validate novel targets that modulate disease-causing gene expression.
Core Business Areas
- Drug Development: Fulcrum's core business revolves around discovering, developing, and commercializing novel therapeutics for rare genetic diseases.
- Research and Discovery: A significant portion of their resources is dedicated to research and discovery efforts to identify new targets and develop potential drug candidates.
Leadership and Structure
Robert J. Gould, Ph.D. is the President and Chief Executive Officer. The company has a standard organizational structure with departments like research, development, clinical operations, and commercial.
Top Products and Market Share
Key Offerings
- Losmapimod: Losmapimod is an oral selective p38u03b1/u03b2 mitogen-activated protein kinase (MAPK) inhibitor being developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Currently in Phase 3 trials. Competitors in the FSHD space are limited, with no approved disease-modifying therapies.
- Other Pipeline Programs: Fulcrum also has other preclinical and clinical programs targeting other genetically defined diseases.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on rare diseases is experiencing significant growth, driven by increased awareness, orphan drug incentives, and advancements in genetic research.
Positioning
Fulcrum Therapeutics is positioned as a company specializing in genetically defined diseases, using a differentiated approach to drug discovery and development. Their competitive advantage lies in their expertise in modulating gene expression.
Total Addressable Market (TAM)
The TAM for FSHD and other rare genetic diseases is substantial, estimated to be in the billions of dollars. Fulcrum is positioned to capture a significant share of this market with successful development and commercialization of its pipeline programs.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Focus on genetically defined diseases
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited product pipeline
- Dependence on clinical trial success
- High cash burn rate
- No currently approved products
Opportunities
- Expansion of pipeline through internal discovery and partnerships
- Potential for orphan drug designation and market exclusivity
- Increasing awareness and diagnosis of rare genetic diseases
- Advancements in gene therapy technologies
Threats
- Clinical trial failures
- Competition from other biopharmaceutical companies
- Regulatory hurdles
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- CRIS
- DTIL
- VIRX
Competitive Landscape
Fulcrum's advantages lie in their focus on genetically defined diseases and their proprietary drug discovery platform. Their disadvantages include their limited product pipeline and dependence on clinical trial success. Competitors have more product diversity.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to investment in the company over time and potential market share.
Future Projections: Future projections depend on the success of clinical trials and the commercialization of Losmapimod and other pipeline programs. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing Losmapimod into Phase 3 clinical trials and expanding their research and discovery efforts.
Summary
Fulcrum Therapeutics is a clinical-stage company with a promising drug candidate (Losmapimod) targeting a significant unmet need (FSHD). Its success hinges on positive Phase 3 results and navigating the complex regulatory landscape. Limited diversity and reliance on one major drug candidate are key challenges to be considered. The company has a unique value proposition that has the potential to generate substantial returns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fulcrum Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. Financial data needs to be updated with the latest filings. The AI-Based rating is based on publicly available information and may not reflect all factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulcrum Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2019-07-18 | CEO, President & Director Mr. Alexander C. Sapir | ||
Sector Healthcare | Industry Biotechnology | Full time employees 45 | Website https://www.fulcrumtx.com |
Full time employees 45 | Website https://www.fulcrumtx.com | ||
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.